New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Wednesday, October 7

Wednesday, October 7, 2026

Everything we published on this day.

67 stories — the front page that day →

SouthernValue on X

Danaher $DHR is combining technology from several of its bioprocessing and life science companies with Lab Robotics startup Automata to launch an AI-powered robotic autonomous research lab. From the Press Release: Danaher's first AI-powered autonomous lab is designed to deliver: - Speed: Up to 8x faster discovery of affinity reagents, helping researchers get from idea to breakthrough sooner - Scale: Unlocking up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents per year as the lab scales - Quality: Each design built in the lab would also be verified, tested and fed back to improve the next, without trading speed for scientific rigor - Sustainability: Over time, this approach is expected to complement traditional immunization-based methods used in the discovery of antibodies and other research tools Based at Abcam, a Danaher company, the lab uses AI to help create new affinity reagents, including antibodies, then builds and tests each one, feeding every result back into the model to improve the next design. The lab brings together industry-leading technologies and expertise from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, in one connected workflow. The device orchestration and robotic automation is the result of collaborative work with Automata*. This continuous design-make-test-learn loop can run in a fraction of the time it takes today, without trading speed for scientific rigor. This approach applies the same test-and-verify discipline of continuous improvement long used across Danaher operations to an AI-enabled laboratory environment. The lab is set to be an early proof point for how Danaher's smart instruments, AI-ready data, and expert agentic systems can accelerate scientific discovery and medical progress.

SouthernValue on X

Morgan Stanley's Wigg: " $GOOG AI infra chief Amin Vahdat says Power lead times are directly gating capacity though GOOG would still rather remain grid-connected than fully self-generate as supplying 1 GW at 99.99%+ reliability on a standalone basis can effectively require ~2 GW of generation because of redundancy requirements. GOOGL is targeting a doubling of token-serving capability every six months. GOOGL’s 7-8 year-old TPUs are still running at 100% utilization despite the company using roughly a 6-year depreciation life,"

Kevin Mak on X

$ABVX Interesting data coming from S&P Markit* (daily short interest based on institutional lending data). Looks like someone established a large position over the past 10 days or so, about 2mm shares or $200M. Given people generally don't like to have single name short exposure over 1-2% of their book (often people size shorts as like ~50 bps), this would be part of a really big book or a really big basket trade. Given the current ABVX-specific situation, it feels weird to be directly betting on the stock falling further from these levels, without any known catalysts around. My best guess is this is part of a "short France" basket trade. But I also can't find any other items of the basket with large changes in short interest to corroborate. Retail Fintwit crowding (correlation with other popular bio names) is likely having an effect as well. Plus rates. Plus biotech degrossing. What I ruled out was a world where this could/would be frontrunning ahead of a possible liquidation (There's a fund with a large ABVX position that took a huge loss on LQDA), but the timing on that is off. In fact pretty much the whole short position was established prior to LQDA crashing. My observation is that the list of items above, plausibly causing weakness in the stock, largely has nothing to do with A) Does the drug work, B) Will the drug sell well. That's what I like about situations like this. ABVX is a large position for us, we've spent a long time recently double/triple checking our fundamental views on the stock and still strongly believe that their key drug, Obefazimod, will be successful even without an acquisition. Hope to have a detailed write-up about that at some point. *I find Markit data to be the most reliable among 3rd party short data, but there are still data anomalies for various reasons. Disclosure: Creek Drive and its affiliated funds holds a long position in ABVX. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.
CCOI 2026-10-07

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

Convequity on X

$NTSK began as a CASB vendor, governing how employees use SaaS applications at the point of use. Years of that work gave it application-specific knowledge of user behavior, data movement, and risk inside cloud apps. That knowledge carries over to AI. Netskope inspects prompts, responses, and file transfers inline and in real time, and it can respond with something more precise than a block: preventing a risky copy-and-paste, stepping up authentication for a sensitive interaction, or coaching the user as they work. The part that matters more comes after the prompt. AI adds autonomy and chaining, so a single human interaction can trigger many machine-executed actions across tools, data stores, and services, often outside one user session. If data is over-permissioned and tools are loosely scoped, an agent can stay inside its allowed permissions and still cause harm faster than a person can intervene. The context Netskope gathers at the interaction can be carried forward to constrain that downstream execution: who the user is, what data is involved, which action was taken, and how risky it looks. So Netskope's edge is that it already knows the user, the data and the action at the moment of the prompt, and it can use that context to limit what an agent does next. It is now building the agent side directly. Its Agentic Broker rates agent actions by risk before they run, and its AI posture management for agents built on AWS, Azure and GCP is still in preview. That is the part to watch.

David Orr on X

I bought the dip in the RV parts company $PATK in 2022. Back then everyone was sure we'd have a recession even though we had super negative real rates. Today $PATK is once again down 50%+, a spot I usually contemplate buying. However, today nobody is talking about a recession (except the perma doomers who don't count) and we have super positive real rates. The housing market is also weak, vs very strong back then. IE Home owners (a big group) suddenly had a lot more cash than they had a few years prior. That setup is gone today, too. I don't think I'll buy $PATK this time. It'll be the first time since I started that I pass on the opportunity. The whole setup here is very concerning for the general market, something I try not to think about too much.

Convequity on X

More $NVDA chips could end up going to SpaceX and other buyers that can borrow at investment-grade rates, leaving neoclouds with fewer chips than they need. SpaceX's planned $40bn chip borrowing shows why. The deal: $SPCX is in early talks for about $10bn of bank loans and $30bn of investment-grade debt, led by Apollo, with Pimco also in talks. It would close in 2027, and the talks could still fall apart. The comparison: in December, Apollo lent about $3.5bn to fund xAI's Colossus 2 chips through a separate company set up just for that deal. The interest rate was about 10% a year. xAI is now part of SpaceX. Investment-grade debt usually costs much less. US investment-grade corporate bonds yield around 6% on average today. The rate on the new $30bn has not been reported, so we don't know the exact saving yet. Why it could be cheaper: lenders would be relying on SpaceX's launch and Starlink businesses to repay, not only on the chips. That is the real financial payoff of putting xAI inside SpaceX. Most GPU buyers can't borrow like that. $CRWV is rated junk (Moody's Ba3, Fitch BB-) and pays 9.25% on its 2030 bonds. Standalone AI labs have no public credit ratings that we could find. Not every neocloud pays up. $NBIS has a GPU loan at a floating benchmark rate plus 2.5%, against CoreWeave's plus 5.5%. Our view: the debate on X is whether this proves AI demand or shows too much leverage. We think the bigger point is cost of capital. When chips are scarce, the buyer that borrows most cheaply can pay for the most of them, and neoclouds paying junk-level rates get squeezed out.

Convequity on X

We agree with Ampersand: an agent is vaporware without deep access to the customer's systems of record. But the result is headless SaaS, where the agent becomes the interface, and headless SaaS does not keep today's economics. Convequity's SaaS Survival Scorecard splits a vendor into three layers, the interface, the workflow and the data, and scores how many of the three it keeps once agents arrive. 1. Deep integration into the system of record is the headless path: the user works through Claude, ChatGPT or another third-party agent, and the vendor keeps workflow and data underneath. Our scorecard calls this Route 2: roughly half the SaaS value is replaced, and the vendor is survivable but diminished unless outcome pricing rescues it. It is the most likely near-term route, and a starting point rather than a stable endpoint. 2. Model companies will expand into the workflow layer to keep growing, and a vendor whose workflows mainly connect other SaaS APIs is highly absorbable. A vendor left with only its data layer is plumbing: it still earns on agent traffic, but it gives up a lot of the value. A vendor that keeps hard-to-replace workflows retains more of it. 3. More agents does not mean more SaaS revenue in every domain. Back-office cost centers like HR, accounting and IT service management have a natural ceiling, because making the work cheaper does not create more of it. Agents cannot create demand for an extra tax filing. Revenue-generating functions like sales and marketing can grow with agents, because extra work there produces extra revenue. 4. Keeping all three layers is rare. $PLTR is the full Route 3 case in our scoring so far, because its ontology works as a quasi system of record and it has model-layer leverage. $PANW approaches Route 3 only within security operations, where sensors and inline enforcement are hard for an agent to absorb. Nearly every other vendor will give up the interface. Ampersand's integration layer and our scorecard describe the same future: the agent is the interface, and the vendor keeps workflow and data. We differ on the economics: a vendor keeps more revenue where the work is unbounded and it holds its workflows, and less where the work is bounded or it is left with only its data.

Fajasy on X

The Pentagon wants every major U.S. military installation to generate its own power. In August 2026, the Army chose five companies for Janus, a program expected to put more than 20 commercial microreactors on military bases. One of the five already builds the reactors for the Navy’s submarines and aircraft carriers, and its stock is down almost 40%. That company is BWX Technologies $BWXT, and even after a 7.6% jump on October 6, the stock is down 38.9% from its $238.42/share peak on April 15. $BWXT didn’t fall alone: → The VanEck Uranium and Nuclear ETF $NLR is down 33.4% from its January high, even after rising 5.5% on October 6. → Curtiss-Wright $CW, which supplies pumps and valves for the same submarines and carriers, is down 30.2% from its July high. So $BWXT got caught in a broader nuclear and defense selloff, but it fell further than both $NLR and $CW after guiding to slower growth in 2027. Meanwhile, $BWXT’s business got stronger: → Guidance up twice: 2026 adjusted EBITDA guidance rose from $645-660M in February to $662-672M in August. → An $8.4B backlog, more than double the $4.0B $BWXT had at the end of 2023. → CEO Rex Geveden calls $BWXT “the sole provider for naval reactors.” The Navy’s 30-year shipbuilding plan, released in May, calls for a new carrier every four years instead of every five. → The Army chose $BWXT’s 20-megawatt reactor for Janus at Fort Campbell, Kentucky, on August 26. On October 5, Prodigy Clean Energy, a Montreal-based developer of factory-built nuclear plants, chose the same reactor for a transportable power plant in New Brunswick. → 2030 targets: $BWXT targeted $5.5-6.0B of revenue and $1.1-1.2B of adjusted EBITDA in 2030. It’s on track to meet or beat all three targets it set in February 2024. Still, here’s what could hold the stock back: → $BWXT expects growth to slow in 2027. Its preliminary framework calls for high-single-digit growth in both revenue and adjusted EBITDA. → Even after the 38.9% drop, $BWXT isn’t cheap in absolute terms. It trades at 20.9x NTM EV/EBITDA and 29.3x earnings. → By CFO Mike Fitzgerald’s count, only a little over half of the revenue growth to 2030 comes from what $BWXT calls its “predictable core,” the programs backed by backlog and long-term contracts. The rest depends on new orders and acquisitions. → $BWXT’s Janus release discloses no dollar figure. Owning reactors is a new business model for $BWXT, with capital commitments it hasn’t disclosed. → No $BWXT insider has bought stock in the open market since at least January 2025, including during the drop from $238 to $135. → The government is running on a continuing resolution through December 11. At $145.70/share, BWXT has a market cap of $13.35B and an EV of $15.0B ($13.35B + $2.05B of debt - $0.40B of cash). It trades at 22.5x 2026 adjusted EBITDA guidance and 30.7x non-GAAP EPS guidance. In return, you get an $8.4B backlog, more than double the $4.0B BWXT had at the end of 2023. And on NTM estimates, its EV/EBITDA has dropped to 20.9x from ~35x in March, back to its 2024 levels. So is the Navy’s reactor supplier on sale, or does the market see a slowdown the numbers don’t show yet? That's what I answer in my new ~6,800 word deep dive on $BWXT! Credit to @GrumpierBTDay for the idea.

Fajasy on X

Read skeptically, Nubeva Technologies $NBVAF (TSXV: $NBVA) is a shrinking software company living off its cash, with an AI decryptor builder that keeps slipping and a license customer that may not have renewed. Read another way, Nubeva is being prepared for a buyer. Here’s what supports the second read: → In March 2024, Netskope $NTSK, now a ~$7.6B company, bought Nubeva’s TLS (web-traffic decryption) technology and five patents for $1M. Greig Bannister, the CTO who co-invented the key-capture patents, followed the technology to Netskope. → In an August 2024 video, CEO Randy Chou said “partnering and M&A groups” from companies worth $20-30B had reached out after the July 2024 CrowdStrike $CRWD outage. → Chou wants all four AI patents granted before any partnership or sale, and two are still pending. → The FY2026 MD&A says Nubeva is “selectively engaging with lighthouse accounts,” meaning “large, high-profile organizations that serve as validation points for the technology,” to make its offering “more attractive for either future expansion or strategic partnership/M&A.” In a June 2025 video, Chou said lighthouse accounts “matter 100%” in a partnership or M&A talk. → Sales and marketing spend was $14,951 for all of FY2026, with $2.49M of cash on hand. In the same June 2025 video, Chou said Nubeva is “really not marketing” until “the patents and everything else comes in.” → The most recent investor deck is from July 2023, and since then Nubeva has communicated mostly through filings, press releases, and the occasional YouTube interview. In other words, it isn’t pitching investors either, which fits a company waiting on a buyer. A longtime investor I spoke with described Chou as reluctant to spend money, PR included, and called a sale to a larger security company the clear end goal. I’d add that Chou, who makes the call, also owns a quarter of the company.

Convequity on X

$NVDA: custom ASICs eat into the GPU share Our scenarios include custom ASICs rising from roughly 20% of the overall AI compute mix toward 40–50%. ABBX records 21.2GW of planned capacity for OpenAI and 13.8GW for Anthropic. Within Anthropic’s plan, ABBX allocates 5GW to AWS Trainium and 5GW to Google/Broadcom TPUs, putting these custom-chip platforms at roughly 72% of its planned capacity. That is a substantial shift in hardware demand if the deployments proceed, although the plans span different timelines. With purchasing concentrated among a few large customers, their decisions to expand on custom silicon could reduce NVIDIA’s share of spending even as the overall AI infrastructure market continues to grow.

Calvin Blissett on X

$BBGI update: Between the recent equity research report and a hedge fund managers conversation with the director of finance and strategy at $BBGI. It seems as if they will pay off their first lien debt and refinance the PIK notes (things that created the timeline and dilute us to oblivion of timeline failed). Director mentioned this route as everyone knows they are on the clock and won’t be able to get fair prices for the assets. +they won’t go bankrupt and the stock should re rate a turn or two when this happens -the Beasley family can continue their horrible governance and keep a great amount of value trapped that otherwise would have to be realized. I’ll probably buy a bit more

Fajasy on X

10 of the 11 insider trades at Magna Mining $MGMNF (TSX: $NICU) since November 2024 were buys, and its CEO says he’s “never sold a share.” CEO Jason Jessup owns 10,441,196 shares, 3.3% of the count, mostly held through Mine Management Partners, a holding company. Five of the 10 buys came from Magna’s November 2024 financing, where insiders including Jessup and Dundee Corporation $DDEJF, a Toronto investment company, took new shares at CAD$1.05. No officer or director sold shares in the open market between November 2024 and March 2026. The only open-market insider buys were incoming CFO Greg Huffman’s 5,200 shares at CAD$2.10-2.35 in March 2026 and director John Seaman’s 10,000 shares at CAD$1.41 in December 2024. The only sale came from TFG Asset Management, part of Tetragon Financial Group $TGONF, which sold 15,000,000 shares at CAD$2.62 (US$27.7M total) on October 3, 2025, two weeks after Magna’s CAD$2.40 share offering. TFG was a 10% holder at the time. Here’s the management team: → Jason Jessup (CEO and Director): 25+ years in mining at FNX Mining, Sandstorm Gold, Premier Royalty, and Inco. At FNX, he “led the team there to restart the mine in the Morrison deposit” at Levack, now Magna’s flagship restart project, and he says FNX returned “about 4200%” from 2000 to 2010. → Jeff Huffman (COO): Joined in November 2023; most recently President and COO of Dumas Contracting, an underground mine contractor. → Greg Huffman (SVP Capital Markets, incoming CFO): Global Head of Mining Sales at Canaccord Genuity $CCORF, the Canadian investment bank, from 2016 to June 2024, then CEO of Nuclear Fuels, a uranium explorer, until its sale in September 2025. Beyond Jessup, the five-person board includes chair Vern Baker, FNX’s former VP of Operations, and Jonathan Goodman, CEO of Dundee, which owns 16.0% of Magna. Greg Huffman will be Magna’s fourth CFO since early 2023, after co-founder Derrick Weyrauch, Ann-Marie Finney (who left in October 2024 after 17 months), and Scott Gilbert, who’s retiring by the end of 2026 after ~2 years. On mgmt's ability to execute, two of Magna’s timelines have slipped: 1) Crean Hill grid power: In November 2025, Jessup said Magna could have power at Crean Hill, its permitted nickel mine, in Q1 2026. In February 2026, he said power would come “hopefully by the end of Q2,” and in August 2026, he moved the target to Q4. 2) Free cash flow: In February 2026, Jessup said “we believe we’ll be generating free cash flow at these prices,” and Q1 2026 brought a US$14.2M free cash outflow, though US$11.0M of it was cash tied up in working capital, mostly money owed to Magna that came in after the quarter. Magna did deliver its other recent milestones, from the Levack resource estimate to the US$99M investment from Alpayana, a Peruvian mining group.

Convequity on X

$SITM supplies timing devices used in optical modules in NVIDIA-based AI data centers. In an AI data center, a clock exists to keep parts synchronized. Training and inference run across thousands of chips in parallel, and each step depends on data arriving at the right moment. When timing slips, GPUs wait, networks stall, and expensive compute goes unused. The move from 800G to 1.6T optical modules shows how this becomes demand for timing parts. Bandwidth does not simply double. The link is split into more lanes running at higher baud rates. Each lane has a tighter jitter budget, and it often adds clock domains for the DSPs, SerDes groups and laser drivers. So each module carries more timing components, and each component has to meet a higher performance requirement. That pushes average selling prices up alongside unit volumes. The same pattern appears in the switches inside that cluster. A high-radix switch multiplies SerDes lanes as bandwidth scales. When the switch increases radix and speed at the same time, it drives more clock domains across the fabric, the ports, and the control logic. Timing content in the switch therefore multiplies rather than rising in step with the size of the cluster. This is why we see continued hypergrowth for SiTime. In NVIDIA-based data centers, SiTime's parts are discrete devices, separate from the GPU and switch ASICs, allowing timing performance to improve independently as system requirements change, and demand for them rises in several places in the rack at once.

Research Roundup Vol. LV

OpenAI’s enterprise privacy push and Synopsys’s Factory 2 royalty model anchor a technology roundup, alongside oil above $100 and Bitcoin’s…

Broken Moats on X

Secular theme of increasing competition in the coffee space, no issue taking a position against SBUX which still carries a premium valuation largely on that premise. My flip side to that, is why also be long Dutch $BROS? Trades worked against you for almost the same reasons - intensifying competition from direct copy cat 7 Brew. But there are many regional players that are aggressively scaling - Summermoon, Foxtail, Lala land, Merrit, etc and those are the ones just geographically close to me but it's a countrywide phenomenon. Turns out yes coffee is habitual and generates good cash returns, but barriers to entry are low. The bidding war for the Salads real estate was insane, and shows how deep pocketed 7 Brew is in their expansion, and being PE backed and not public means they might be less disciplined...... So why Bros? There might still be potential there, the model is efficient and a cult service culture, but even at current levels I find the valuation difficult to digest not to mention overhangs from GLP1s, affordability/gas prices